Intratumoral collagen supports tumor progression

Abstract

Solid tumors are characterized by extensive extracellular matrix (ECM) remodeling prominently featuring massive collagen deposition. This dense collagen network does not act as inert scaffolding but actively orchestrates critical aspects of tumor progression and therapy resistance, thereby shaping the fate of cancer cells. Collagen influences cellular behavior through multiple mechanisms, including providing structural rigidity, modulating mechanotransduction signaling pathways, creating physical barriers to immune cell infiltration and drug penetration, and serving as a reservoir for signaling molecules. Here, we discuss recent findings regarding the critical roles of collagen in tumors and potential therapies for armored and cold tumors, a refractory subset demonstrating high collagen deposition and low immune infiltration.

Keywords

Armored and cold tumors / collagen / immune exclusion / tumor microenvironment

References

[1] Su H, Karin M. Collagen architecture and signaling orchestrate cancer development. Trends Cancer 2023; 9(9): 764-73. [PMID: 37400314 DOI: 10.1016/j.trecan.2023.06.002]

[2] Sleeboom JJF, van Tienderen GS, Schenke-Layland K, van der Laan LJW, Khalil AA, et al. The extracellular matrix as hallmark of cancer and metastasis: from biomechanics to therapeutic targets. Sci Transl Med 2024; 16(728): eadg3840. [PMID: 38170791 DOI: 10.1126/scitranslmed.adg3840]

[3] Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: perspectives and challenges. Cancer Cell 2023; 41(3): 434-49. [PMID: 36917949 DOI: 10.1016/j.ccell.2023.02.015]

[4] Chitty JL, Cox TR. The extracellular matrix in cancer: from understanding to targeting. Trends Cancer 2025;S2405-8033(25)00126-8. [PMID: 40467384 DOI: 10.1016/j.trecan.2025.05.003]

[5] Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean M-C, Validire P, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 2012; 122(3): 899-910. [PMID: 22293174 DOI: 10.1172/JCI45817]

[6] O’Connor RS, Hao X, Shen K, Bashour K, Akimova T, et al. Substrate rigidity regulates human T cell activation and proliferation. J Immunol 2012; 189(3): 1330-9. [PMID: 22732590 DOI: 10.4049/jimmunol.1102757]

[7] Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141(1): 52-67. [PMID: 20371345 DOI: 10.1016/j.cell.2010.03.015]

[8] Wang Y, Zhang F, Qian Z, Jiang Y, Wu D, et al. Targeting collagen to optimize cancer immunotherapy. Exp Hematol Oncol 2025; 14(1): 101. [PMID: 40721833 DOI: 10.1186/s40164-025-00691-y]

[9] Mei J, Cai Y, Xu R, Li Q, Chu J, et al. Conserved immuno-collagenic subtypes predict response to immune checkpoint blockade. Cancer Commun (Lond) 2024; 44(5): 554-75. [PMID: 38507505 DOI: 10.1002/cac2.12538]

[10] Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, et al. Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Cancer Cell 2024; 42(12): 2098-112.e4. [PMID: 39577421 DOI: 10.1016/j.ccell.2024.10.016]

[11] Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018; 24(5): 541-50. [PMID: 29686425 DOI: 10.1038/s41591-018-0014-x]

[12] Baldari S, Di Modugno F, Nisticò P, Toietta G. Strategies for efficient targeting of tumor collagen for cancer therapy. Cancers (Basel) 2022; 14(19): 4706. [PMID: 36230627 DOI: 10.3390/cancers14194706]

[13] Mei J, Cai Y, Zhu H, Jiang Y, Fu Z, et al. High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer. NPJ Breast Cancer 2024; 10(1): 11. [PMID: 38280882 DOI: 10.1038/s41523-024-00618-6]

[14] Shen B, Mei J, Xu R, Cai Y, Wan M, et al. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma. Pathol Res Pract 2024; 256: 155267. [PMID: 38520953 DOI: 10.1016/j.prp.2024.155267]

[15] Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med 2023; 29(4): 888-97. [PMID: 37012549 DOI: 10.1038/s41591-023-02284-w]

[16] Mei J, Yang K, Zhang X, Luo Z, Tian M, et al. Intratumoral collagen deposition supports angiogenesis suggesting anti-angiogenic therapy in armored and cold tumors. Adv Sci (Weinh) 2025; 12(10): e2409147. [PMID: 39823457 DOI: 10.1002/advs.202409147]

[17] Wan M, Mei J, Cai Y, Zhou J, Xue N, et al. Targeting IGF1R overcomes armored and cold tumor microenvironment and boosts immune checkpoint blockade in triple-negative breast cancer. Adv Sci (Weinh) 2025; e01341. [PMID: 40679093 DOI: 10.1002/advs.202501341]

[18] van Leeuwen RWF, Jansman FGA, van den Bemt PMLA, de Man F, Piran F, et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol 2015; 26(5): 992-7. [PMID: 25628444 DOI: 10.1093/annonc/mdv029]

[19] Mei J, Chu J, Yang K, Luo Z, Yang J, et al. Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade. J Immunother Cancer 2024; 12(9): e009327. [PMID: 39244215 DOI: 10.1136/jitc-2024-009327]

[20] Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol 2019; 5(7): 1020- 7. [PMID: 31145418 DOI: 10.1001/jamaoncol.2019.0892]

[21] Pedersen L, Idorn M, Olofsson GH, Lauenborg B, Nookaew I, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab 2016; 23(3): 554-62. [PMID: 26895752 DOI: 10.1016/j.cmet.2016.01.011]

[22] Luo Z, Mei J, Wang X, Wang R, He Z, et al. Voluntary exercise sensitizes cancer immunotherapy via the collagen inhibition-orchestrated inflammatory tumor immune microenvironment. Cell Rep 2024; 43(9): 114697. [PMID: 39217611 DOI: 10.1016/j.celrep.2024.114697]

[23] Mei J, Luo Z, Cai Y, Wan R, Qian Z, et al. Altered atlas of exercise-responsive microRNAs revealing miR-29a-3p attacks armored and cold tumors and boosts anti-B7-H3 therapy. Research (Wash DC) 2025; 8: 0590. [PMID: 39845707 DOI: 10.34133/research.0590]

[24] Guo Z, Saw PE, Jon S. Non-invasive physical stimulation to modulate the tumor microenvironment: unveiling a new frontier in cancer therapy. BIOI 2024; 5(1). [DOI: 10.15212/bioi-2024-0012]